Prognostic implications of receptor discordance between primary and recurrent breast cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491216 | ||
| 003 | CHVBK | ||
| 005 | 20210128100509.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0759-2 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0759-2 | ||
| 245 | 0 | 0 | |a Prognostic implications of receptor discordance between primary and recurrent breast cancer |h [Elektronische Daten] |c [Akiko Matsumoto, Hiromitsu Jinno, Takeshi Murata, Tomoko Seki, Maiko Takahashi, Tetsu Hayashida, Kaori Kameyama, Yuko Kitagawa] |
| 520 | 3 | |a Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10-40%, although its prognostic relevance remains to be elucidated. Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−). Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2%, respectively. Overall, 14 patients (25.5%) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5months, p=0.037, PgR: 141.0 vs. 24.4months, p=0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4months, p=0.051). Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10-30%. A gain in HR status was significantly associated with better prognosis. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Breast cancer |2 nationallicence | |
| 690 | 7 | |a Receptor |2 nationallicence | |
| 690 | 7 | |a Discordance |2 nationallicence | |
| 690 | 7 | |a Recurrence |2 nationallicence | |
| 690 | 7 | |a Prognosis |2 nationallicence | |
| 690 | 7 | |a Biopsy |2 nationallicence | |
| 700 | 1 | |a Matsumoto |D Akiko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Jinno |D Hiromitsu |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Murata |D Takeshi |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Seki |D Tomoko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Takahashi |D Maiko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Hayashida |D Tetsu |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kameyama |D Kaori |u Division of Pathological Diagnosis, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kitagawa |D Yuko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/4(2015-08-01), 701-708 |x 1341-9625 |q 20:4<701 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0759-2 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0759-2 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Matsumoto |D Akiko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Jinno |D Hiromitsu |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Murata |D Takeshi |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Seki |D Tomoko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takahashi |D Maiko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hayashida |D Tetsu |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kameyama |D Kaori |u Division of Pathological Diagnosis, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kitagawa |D Yuko |u Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/4(2015-08-01), 701-708 |x 1341-9625 |q 20:4<701 |1 2015 |2 20 |o 10147 | ||